Vericel Corp (VCEL)

• Market cap: $2.07B
• 1 day: 1.00%
• 5 days: -0.24%
• 1 month: -13.38%
• 3 months: -30.20%
• 6 months: 1.38%
• Year to date: -25.19%
• 1 year: -10.87%
• 5 years: 224.90%
• 10 years: 1,467.68%
• Sector: Healthcare
• Industry: Biotechnology

About: Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Employees: 357

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

200% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 3 (+2) [Q4]

50% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 30

33% more capital invested

Capital invested by funds: $2.15B [Q3] → $2.86B (+$715M) [Q4]

22% more repeat investments, than reductions

Existing positions increased: 100 | Existing positions reduced: 82

4% more funds holding

Funds holding: 263 [Q3] → 273 (+10) [Q4]

2.8% more ownership

Funds ownership: 104.46% [Q3] → 107.27% (+2.8%) [Q4]

16% less call options, than puts

Call options by funds: $6.28M | Put options by funds: $7.49M

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $51 24% upside
• Avg. target: $59 44% upside
• High target: $67 63% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Truist Securities Richard Newitter 54% 1-year accuracy 26 / 48 met price target	24% upside $51	Buy Maintained	11 Apr 2025
HC Wainwright & Co. Swayampakula Ramakanth 23% 1-year accuracy 44 / 192 met price target	46% upside $60	Buy Reiterated	28 Feb 2025
Canaccord Genuity Caitlin Cronin 14% 1-year accuracy 2 / 14 met price target	63% upside $67	Buy Maintained	3 Feb 2025